Oppenheimer analyst Andreas Argyrides initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating and announces Price Target of $102.
Oppenheimer Initiates Coverage On Keros Therapeutics With Outperform Rating, Announces Price Target of $102
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.